Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice

• मुख्य लेखकों: L.S. van der Schoot (लेखक), J.J. Janssen (लेखक), M.T. Bastiaens (लेखक), A. de Boer-Brand (लेखक), C. Christiaansen-Smit (लेखक), D.N.H. Enomoto (लेखक), R. Hovingh (लेखक), R.A. Tupker (लेखक), M.M.B. Seyger (लेखक), L.M. Verhoef (लेखक), J.M.P.A. van den Reek (लेखक), E.M.G.J. de Jong (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Background Dose reduction (DR) of adalimumab, etanercept and ustekinumab has proven to be (cost-)effective in psoriasis patients with low disease activity. Further implementation is needed to establish application of DR for eligible patients. Objectives To evaluate the implementation of protocolized...